Gary Gilkeson, MD

Gary Gilkeson, MD
Associate Dean, Faculty Affairs
Professor, Microbiology and Immunology
 

Contact
96 Jonathan Lucas Street, Suite 912
PO Box 250637
Charleston, SC 29425
gilkeson@musc.edu

Education
MD, Southwestern Medical College

Biography and Research Interests
Dr. Gilkeson is a Professor of Medicine/Microbiology and Immunology and an Associate Dean for Faculty Affairs and Faculty Development.  Dr. Gilkeson is board certified in Internal Medicine with a sub-specialty of Rheumatology.  He is Chair of the Medical Advisory Board for the Lupus Foundation of America and on their Board of Directors.  Dr. Gilkeson’s research focuses on disparities in morbidity and mortality in African Americans with lupus.  His group is performing genetic/environmental assessments of factors leading to lupus and its complications.  This work has led to his work in Sierra Leone.

Project Involvement

Bo, Sierra Leone
The current dogma is that there is very little lupus in West Africa, the ancestral home of African Americans in whom lupus is a prevalent disease.  The Gullah population in South Carolina is known to have ancestral and cultural ties to the people of Sierra Leone.  Dr. Gilkeson is assessing the prevalence of lupus in Bo, Sierra Leone in comparison to the Gullah population on the Sea Islands of South Carolina. Gilkeson’s team, in their trips to Bo, obtained biologic samples (serum/DNA) from young women in Bo to assess autoantibody prevalence and their immunogenetics compared to controls in South Carolina and Georgia.  They are also obtaining soil and water samples to assess for environmental contaminants.   This research fits into the bigger picture of genes versus environmental triggers in lupus. 

Nanjing, China
Dr. Gilkeson is part of an MUSC partnership with the Nanjing Drum Tower Hospital collaborating with Dr. Linyung Sun to assess the efficacy of mesenchymal stem cell transplantation as a treatment for lupus.  Dr. Gilkeson has visited Nanjing three times and Dr. Sun has been to MUSC multiple times as part of this collaboration.

Related Media

Selected Publications

  1. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years experience. Wang D, Zhang H, Liang J, Li X, Feng X, Wang H, Hua B, Liu B, Lu L, Gilkeson GS, Silver RM, Chen W, Shi S, Sun L.Cell Transplant. 2012 Oct 31. [Epub ahead of print]PMID:23127470
  2. Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Kaufman KM, Zhao J, Kelly JA, Hughes T, Adler A, Sanchez E, Ojwang JO, Langefeld CD, Ziegler JT, Williams AH, Comeau ME, Marion MC, Glenn SB, Cantor RM, Grossman JM, Hahn BH, Song YW, Yu CY, James JA, Guthridge JM, Brown EE, Alarcón GS, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri MA, Reveille JD, Vilá LM, Anaya JM, Boackle SA, Stevens AM, Freedman BI, Criswell LA, Pons-Estel BA; on behalf of the Argentine Collaborative Group, Lee JH, Lee JS, Chang DM, Scofield RH, Gilkeson GS, Merrill JT, Niewold TB, Vyse TJ, Bae SC, Alarcón-Riquelme ME; on behalf of the BIOLUPUS network, Jacob CO, Sivils KM, Gaffney PM, Harley JB, Sawalha AH, Tsao BP.Ann Rheum Dis. 2012 Aug 24. [Epub ahead of print]PMID:22904263
  3. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Tang Y, Ma X, Zhang H, Gu Z, Hou Y, Gilkeson GS, Lu L, Zeng X, Sun L.Clin Dev Immunol. 2012;2012:826182. doi: 10.1155/2012/826182. Epub 2012 Aug 27.PMID: 22966240